within Pharmacolibrary.Drugs.N_NervousSystem.N06A_Antidepressants.N06AB04_Citalopram;

model Citalopram
  extends Pharmacolibrary.Pharmacokinetic.Models.PK_2C_enteral(
    weight = 70,
    F = 0.8,
    Cl = 6.4166666666666665e-06,
    adminDuration = 600,
    adminMass = 40 / 1000000,
    adminCount = 1,
    Vd = 0.0123,
    Cmin = 0.001,
    Cmax = 0.01,
    Ctox_peak = 0.02,
    Ctox_trough = 0.01,
    ka = 0.004333333333333333,
    Tlag = 10.200000000000001,
    Vdp = 0.0263,
    k12 = 9.13888888888889e-06,
    k21 = 9.13888888888889e-06);

  annotation (Documentation(
    info       = "<html><body><table><tr><td>name:</td><td>Citalopram</td></tr><tr><td>ATC code:</td><td>N06AB04</td></tr><td>route:</td><td>oral</td></tr>
    <tr><td>compartments:</td><td>2</td></tr>
    <tr><td>dosage:</td><td>40</td><td>mg</td></tr>
    <tr><td>volume of distribution:</td><td>12.3</td><td>L</td></tr>
    <tr><td>clearance:</td><td>0.33</td><td>L/h/kg</td></tr>
    <tr><td colspan='3'>other parameters in model implementation</td></tr>
    </table><p>Citalopram is a selective serotonin reuptake inhibitor (SSRI) used primarily in the treatment of major depressive disorder, anxiety disorders, and other mood disorders. It is approved for clinical use and remains widely prescribed for these indications.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters reported for healthy adult volunteers, both male and female, following single and multiple oral doses.</p><h4>References</h4><ol><li><p>Velez de Mendizabal, N, et al., &amp; Bies, RR (2015). A population PK model for citalopram and its major metabolite, N-desmethyl citalopram, in rats. <i>Journal of pharmacokinetics and pharmacodynamics</i> 42(6) 721–733. DOI:<a href=\"https://doi.org/10.1007/s10928-015-9448-7\">10.1007/s10928-015-9448-7</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26395999/\">https://pubmed.ncbi.nlm.nih.gov/26395999</a></p></li><li><p>Akil, A, et al., &amp; Lyketsos, CG (2016). A population pharmacokinetic model for R- and S-citalopram and desmethylcitalopram in Alzheimer&#x27;s disease patients with agitation. <i>Journal of pharmacokinetics and pharmacodynamics</i> 43(1) 99–109. DOI:<a href=\"https://doi.org/10.1007/s10928-015-9457-6\">10.1007/s10928-015-9457-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/26611790/\">https://pubmed.ncbi.nlm.nih.gov/26611790</a></p></li><li><p>Yu, BN, et al., &amp; Zhou, HH (2003). Pharmacokinetics of citalopram in relation to genetic polymorphism of CYP2C19. <i>Drug metabolism and disposition: the biological fate of chemicals</i> 31(10) 1255–1259. DOI:<a href=\"https://doi.org/10.1124/dmd.31.10.1255\">10.1124/dmd.31.10.1255</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/12975335/\">https://pubmed.ncbi.nlm.nih.gov/12975335</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>10/2026 Pharmacolibrary 26.09: model of Drugs.ATC.N.N06AB04 folded in (Drugs.ATC removed)</li><li>06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
    
end Citalopram;
